GOSS logo

Gossamer Bio, Inc. Stock Price

NasdaqGS:GOSS Community·US$590.8m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 22 Fair Values set on narratives written by author
Create a narrative

GOSS Share Price Performance

US$2.50
1.45 (138.10%)
83.3% undervalued intrinsic discount
US$15.00
Fair Value
US$2.50
1.45 (138.10%)
83.3% undervalued intrinsic discount
US$15.00
Fair Value
Price US$2.50
AnalystHighTarget US$15.00
AnalystConsensusTarget US$8.86
AnalystLowTarget US$1.25

GOSS Community Narratives

AnalystHighTarget·
Fair Value US$15 83.9% undervalued intrinsic discount

Seralutinib Will Succeed As Aging Populations Drive PAH Demand

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystConsensusTarget·
Fair Value US$8.86 72.8% undervalued intrinsic discount

Phase III Trials And Global Collaborations Will Expand Treatment Horizons

0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AnalystLowTarget·
Fair Value US$1.25 92.8% overvalued intrinsic discount

Biotech Regulation And Cash Burn Will Constrain Future Prospects

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative

Recent GOSS News & Updates

Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout

Sep 09

Revenues Not Telling The Story For Gossamer Bio, Inc. (NASDAQ:GOSS) After Shares Rise 26%

Aug 22
Revenues Not Telling The Story For Gossamer Bio, Inc. (NASDAQ:GOSS) After Shares Rise 26%
User avatar

Phase III Trials And Global Collaborations Will Expand Treatment Horizons

Successful Phase III study enrollment and collaboration enhance market reach, promising revenue growth through potential positive efficacy results and expanded indications.

Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD

Feb 14

Gossamer Bio, Inc. Key Details

US$40.2m

Revenue

US$0

Cost of Revenue

US$40.2m

Gross Profit

US$179.0m

Other Expenses

-US$138.7m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-0.60
Gross Margin
100.00%
Net Profit Margin
-344.81%
Debt/Equity Ratio
-429.5%

Gossamer Bio, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 
View more competitors

Snowflake Analysis

Fair value with low risk.

3 Risks
2 Rewards
View Full Analysis

About GOSS

Founded
2015
Employees
145
CEO
Faheem Hasnain
WebsiteView website
www.gossamerbio.com

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Market Insight

Header cover image

✨Rare Earths: Tiny Market, Outsized Influence

Richard Bowman avatarRichard Bowman
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Last Week
⚡ Utilities: Defensive Dividends Meet the AI Power Surge

⚡ Utilities: Defensive Dividends Meet the AI Power Surge

U.S. Market Performance

  • 7 Days: 1.1%
  • 3 Months: 8.9%
  • 1 Year: 18.9%
  • Year to Date: 15.1%
Over the last 7 days, the market has risen 1.1%, driven by gains of 1.9% in the Information Technology sector. The market is up 19% over the last 12 months. Earnings are forecast to grow by 15% annually. Market details ›